PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.71%
G&A change of 30.71% while AXSM maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
-38.54%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
25.41%
Operating expenses growth above 1.5x AXSM's 6.62%. Michael Burry would check for inefficiency.
25.41%
Total costs growth above 1.5x AXSM's 8.31%. Michael Burry would check for inefficiency.
-10.64%
Interest expense reduction while AXSM shows 24.56% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
EBITDA decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Operating income decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
353.66%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
100.00%
Pre-tax income growth exceeding 1.5x AXSM's 17.64%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-610.74%
Tax expense reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine advantage.
610.74%
Net income growth exceeding 1.5x AXSM's 19.26%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
609.26%
EPS growth exceeding 1.5x AXSM's 20.49%. David Dodd would verify competitive advantages.
609.26%
Diluted EPS growth exceeding 1.5x AXSM's 20.49%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.